NUVL News

The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more

Nuvalent, a preclinical oncology biotech developing small molecule kinase inhibitors, raised $166 million by offering 9.8 million shares at $17, within the range of $16 to $18. The company offered 0.9 million more shares than anticipated. Nuvalent focuses on clinically proven kinase targets that have demonstrated efficacy and received FDA approval. It seeks to improve upon the...read more

Nuvalent, a preclinical oncology biotech developing small molecule kinase inhibitors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Nuvalent would command a fully diluted market value of $835 million. Nuvalent focuses on...read more

After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million.  Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to raise $25 million at a $54 million market cap. This oncology biotech develops RNA therapeutics for the treatment of solid...read more